Sitemap| Attacking Cancer with Specific Anti-Tumor Pathways |
BEVERLY, MA - October 20, 2009 - Cellceutix Corporation (OTCBB: CTIX) today announced that data recently presented by the Company at the American Association for Cancer Research (AACR) along with other data developed by the Company indicate that Kevetrin is selectively targeting signal transduction very specific anti-tumor pathways, such as AKT and p38 MAP kinase. The data presented at the AACR showed that Kevetrin was less cytotoxic than paclitaxel, cisplatin and 5FU while having better, more potent, anti-tumor activity in two multi-drug resistant lung cancer cell lines. This indicates that Kevetrin is not acting primarily as a cytotoxic agent but may be targeting specific components of the signal transduction pathways, such as AKT and p38 MAP kinase. The Company is continuing to explore other potential targets. Other data developed by the Company indicate that Kevetrin has potent ant-tumor activity in one cell line (MDA-MB--231) despite only partially inhibiting AKT in that cell line. AKT and p38 MAP kinase are important targets in fighting cancers. Kinases are molecules that play a role in many aspects of cell function. The activity of AKT, a protein kinase, is increased in many tumors thereby increasing the survival of cancer cells that would otherwise die. p38MAP is another protein kinase important for tumor cell survival. On October 9, 2009, an abstract describing animal model experiments with Kevetrin in multi-drug resistant lung cancer cell lines was one of four selected in a press release by The American Association for Cancer Research (AACR) at their first Frontiers in Basic Cancer Research Meeting. http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=1584
|